Overview: GD2 IgM TestIntroduction: The GD2 IgM Test tests for GD2 IgM antibodies to diagnose acute autoimmune neuropathies, causing nerve pain or muscle weakness, aiding in treatment planning. Affecting 1 in 100,000 people with neuropathies, these conditions pose diagnostic challenges due to rapid onset. Following 2023 American Academy of Neurology (AAN) guidelines, it uses ELISA for high sensitivity, supporting immunology screening. This test is essential for diagnosis, therapy planning, and improving outcomes in neurology.
Other Names: GD2 IgM Antibody Test, Acute Neuropathy Assay.
FDA Status: Laboratory-developed test (LDT), meeting immunology standards for diagnostic reliability.
Historical Milestone: Autoantibody testing began in the 1980s with research by Yu, who linked GD2 to neuropathies. ELISA advancements in the 2000s by Thermo Fisher improved detection, surpassing earlier Western blot methods.
Purpose: Detects GD2 IgM antibodies to diagnose acute neuropathies, guides immunosuppressive therapy, and evaluates patients with nerve pain, aiming to manage symptoms.
Test Parameters: GD2 IgM antibody levels
Pretest Condition: No special preparation required. Collect serum. Report history of neurological symptoms.
Specimen: Serum (SST, 2-5 mL); 2 mL serum in SST. Transport in a biohazard container.
Sample Stability at Room Temperature: 6 hours
Sample Stability at Refrigeration: 1 week
Sample Stability at Frozen: 1 month
Medical History: Document nerve pain or muscle weakness. Include current medications or autoimmune history.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., paralysis), and sample collection risks.
Procedural Considerations: Uses ELISA to measure GD2 IgM, requiring labs with plate readers. Results available in 3-5 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or contamination can affect results. Medications may alter levels, requiring correlation.
Clinical Significance: Elevated GD2 IgM confirms acute neuropathy, guiding therapy. Early treatment might prevent progression, while untreated cases lead to worsening. Normal levels may require other antibody tests.
Specialist Consultation: Consult a neurologist for interpretation.
Additional Supporting Tests: Nerve conduction study, EMG, or autoimmune panel to confirm diagnosis.
Test Limitations: Specific to GD2 IgM; correlation with symptoms needed. False positives possible with cross-reactivity.
References: AAN Guidelines, 2023; Neurology, Yu RK, 2022.
